CONTACT: D. Scott Buchanan
4-D Neuroimaging
(858) 453-6300


4-D NEUROIMAGING ANNOUNCES THE TERMINATION OF ITS REPORTING OBLIGATION AND STOCK REGISTRATION

San Diego, California, March 3, 2004 -- 4-D Neuroimaging (“4-D”) (OTC: FDNUV) announced today that in order to maximize its ability to serve its growing customer base and to develop further improvements to its widely used MEG technology, it has completed a "going private" transaction. President and CEO D. Scott Buchanan, Ph.D. commented "The resources required to maintain our compliance with the increasingly complex regulations imposed on publicly-held companies by the SEC have grown rapidly over the past few years. These efforts now consume a far greater percentage of our management and financial resources than can be justified by the benefits derived." Following a 1200-to-1 reverse split of its stock the Company terminated its reporting obligations and the registration of its common stock with the SEC thereby freeing resources to apply to areas that add greater value to the Company.

Buchanan said "Our shareholders and our customers will be far better served by the Company directing the resource freed by this change into activities that will contribute directly to the now-accelerating progress in the clinical and research applications of MEG." The Company plans to continue the same strict accounting practices and conservative approach to revenue recognition and cash management that has served it well during its tenure as a publicly held firm.

4-D Neuroimaging, headquartered in San Diego, CA, and with a European Sales and Service office in Aachen, Germany, is dedicated to the development of Magnetoencephalography (“MEG”) systems, which utilize superconducting sensors to measure magnetic fields in the human brain and body and assist in the diagnosis of a potentially broad range of medical disorders. Its main products, the Magnes 2500 WH and Magnes 3600 WH, allow examination of the functioning of the entire brain at once, and are designed for evaluating all patients including those that are critically ill. Additional information about 4-D and its products can be found on its web site: www.4dneuroimaging.com.

This press release may contain forward-looking statements that involve risks and uncertainties. Actual results may differ from what is expressed or implied here. Risks and uncertainties that could cause or contribute to such differences include, but are not limited to, 4-D’s, market acceptance of new applications, competition, obtaining routine reimbursements from third party payers, regulatory approvals and other factors. These and other risks are described in detail in 4-D's filings with the U.S. Securities and Exchange Commission. 4-D is not obligated to publicly update or revise these forward-looking statements.